Click here to access press releases from Astellas Pharma Inc. located in Tokyo, Japan.
-
Nov 20, 2018
Navigation Acuity Tool to be Developed by Astellas US LLC and AONN+
-
Nov 19, 2018
- Abstracts include updated results from Phase 1 study of gilteritinib in patients with newly diagnosed AML -
-
-
-
Oct 4, 2018
Three innovators working to change cancer care awarded a combined $100,000 in grants following live pitch to a panel of judges that included celebrity entrepreneur Bill Rancic
-
Sep 25, 2018
Astellas ranked in recognition of its commitment and support for working mothers
-
Sep 24, 2018
Astellas recognized by Great Place to Work® Institute
-
Sep 24, 2018
Results from the PROSPER trial show a median metastasis-free survival (MFS) of 36.6 months for enzalutamide plus androgen deprivation therapy (ADT) vs 14.7 months for men who received placebo plus ADT(1)
-
Sep 21, 2018
Bill and Giuliana Rancic to Lend Expertise, Passion and Personal Cancer Experience to Inspire Fellow Entrepreneurs
-
-
Sep 14, 2018
--Additional marketing award received for Best Video/TV Campaign--
-
-
Sep 12, 2018
Winner Will Attend Live Taping of ABC's "Dancing with the Stars"
-
-
-
Aug 22, 2018
Amendments accelerate anticipated primary completion dates for both ARCHES and EMBARK trials
-
-
Aug 10, 2018
Acquisition furthers Astellas' commitment to innovation in ophthalmology with addition of novel gene therapy program for glaucoma
-
-
Jul 23, 2018
Dr. Halit Bander named VP, Oncology, Medical Affairs; Moyra Knight named VP, Corporate Communications; Maribeth Landwehr named Executive Director, Corporate Communications
-
Jul 13, 2018
First and Only Oral Treatment FDA-Approved for Both Non-Metastatic and Metastatic CRPC
-
Jul 9, 2018
-Enrollment of EV-201 Pivotal Trial Cohort Designed to Support Potential Expedited Registration Pathway in the U.S. Completed-
-
Jun 19, 2018
Employees Also Raised More Than $55,000 at Third Annual "One Astellas Spirit Run" for Seven Charitable Organizations
-
-
Jun 3, 2018
-Updated Data from Phase 1 EV-101 Study Highlighted in ASCO 2018 Oral Presentation Support Rapid Development Program and Ongoing Pivotal Study-
-
May 31, 2018
2018 Challenge Will Award a Total of $100,000 in New Grants to Help Reduce the Unequal Burden of Cancer
-
-
-
May 15, 2018
Joins Company's Executive Leadership Team
-
-
-
-
-
-
Apr 18, 2018
Asset Transfer was Completed on April 12, 2018
-
-
Mar 28, 2018
Dragovic was previously Vice President, Ethics & Compliance Americas
-
-
Mar 19, 2018
sNDA Seeks to Expand the Indication of XTANDI to include Men with Non-metastatic CRPC
-
Mar 15, 2018
Barretto-Ko was previously Senior Vice President, International Operations
-
-
Feb 13, 2018
Acquisition enables Astellas to fully utilize proprietary technology to produce pluripotent stem cells that have the potential to lower immunological rejection in numerous therapeutic areas
-
-
-
Jan 29, 2018
- A total of 10 abstracts and one trial in progress (TIP) across various cancers to be presented during oral and poster sessions -
-
-
-
-
-
.svg)
